Experiments from the current study showed that CCL3 and CCL4 are increased and responsible for Btk and NF-κB activation, and ultimately, chemoresistance of EBNA2-expressing DLBCL cells. The gene discussed is CCL3; the disease is diffuse large B-cell lymphoma.